Skip to main content
Cellular and Molecular Life Sciences: CMLS logoLink to Cellular and Molecular Life Sciences: CMLS
. 2001 May;58(5):728–736. doi: 10.1007/PL00000896

Histone acetylation and disease

S Timmermann 1, H Lehrmann 1, A Polesskaya 1, A Harel-Bellan 1
PMCID: PMC11337357  PMID: 11437234

Abstract.

Differential acetylation of histones and transcription factors plays an important regulatory role in developmental processes, proliferation and differentiation. Aberrant acetylation or deacetylation leads to such diverse disorders as leukemia, epithelial cancers, fragile X syndrome and Rubinstein-Taybi syndrome. The various groups of histone acetyltransferases (CBP/p300, GNAT, MYST, nuclear receptor coactivators and TAFII250) and histone deacetylases are surveyed with regard to their possible or known involvement in cancer progression and human developmental disorders. Current treatment strategies are discussed, which are still mostly limited to histone deacetylase inhibitors such as trichostatin A and butyrate.

Keywords: Key words. HAT; HDAC; histone acetylation; butyrate; TSA; dietary fiber; leukemia; fragile X syndrome.


Articles from Cellular and Molecular Life Sciences: CMLS are provided here courtesy of Springer

RESOURCES